CatalYm Closes EUR 50 Million Series C Financing
Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"
24-Nov-2022 -
CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...
cancer
cancer immunotherapeutics
monoclonal antibodies
+1